Adenovirus CMV Expression System

<table>
<thead>
<tr>
<th>Product Description</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete Adenovirus CMV Expression System</td>
<td>A100</td>
</tr>
<tr>
<td>Partial Adenovirus CMV Expression System</td>
<td>A110</td>
</tr>
<tr>
<td>Partial Adenovirus CMV Expression System</td>
<td>A120</td>
</tr>
<tr>
<td>Supplemental Kit for All Adenovirus Systems</td>
<td>A097</td>
</tr>
<tr>
<td>Supplemental Kit for All Adenovirus Systems</td>
<td>A098</td>
</tr>
<tr>
<td>Supplemental Kit for All Adenovirus Systems</td>
<td>A099</td>
</tr>
</tbody>
</table>
Notice to the Purchaser

The products are for research use only. Use in and/or for diagnostics or therapeutics is strictly prohibited. By opening and using the product, the purchaser agrees to the following: The components in this kit may not be distributed, resold, or modified for resale without prior written approval from Applied Biological Materials (abm) Inc. If you do not agree to the above conditions, please return the UNOPENED product to abm Inc. within ten (10) days of receipt for a full refund. The information in this document is subject to change without notice and should not be construed as a commitment by abm Inc. or its affiliated corporations. In no event shall abm Inc. or its affiliated corporations be liable for incidental or consequential damages in connection with or arising from the use of this manual and product.

**abm Inc. products are warranted to meet our QC testing standards at the time of shipment.** Notice of problematic products must be made to abm Inc. within 15 days of receipt of the product. This product warranty limits abm Inc.’s liability to the replacement of the product only.

Technical Support

For more information on abm Inc. products, please visit our website:

http://www.abmGood.com

For additional information or technical assistance, please call or email us at:

**Applied Biological Materials, Inc.**

Phone: (604) 247-2416
1-866-757-2414

Fax: (604) 247-2414

E-mail: technical@abmGood.com
Biosafety

All Adenoviral Expression Systems provided by abm Inc. include the following safety features:

• The entire E1 gene is deleted from the adenovector (pAdeno). Expression of the E1 protein is required for the expression of the other viral genes, and thus viral replication only occurs in cells that express E1, like 293 cells (Graham et al., 1977; Kozarsky and Wilson, 1993; Krougliak and Graham, 1995).

• Recombinant adenovirus produced from abm Inc.'s adenoviral cloning systems is replication-deficient in mammalian cells that do not express the E1 proteins (Graham et al., 1977; Kozarsky and Wilson, 1993; Krougliak and Graham, 1995).

• Since recombinant adenovirus is replication-incompetent, the presence of the viral genome will be transient and will eventually be degraded or diluted out as cell division occurs.

• Adenovirus does not integrate into the host genome upon transduction, avoiding any possible insertional mutations.

Despite the safety features discussed above, it is highly recommended that all manipulation with adenoviral vectors, including viral production and transduction, be performed under Biosafety Level 2 (BL-2). All published BL-2 guidelines with proper waste decontamination should be strictly followed. In addition, exercise extra caution when creating adenovirus carrying potentially harmful or toxic genes (e.g. oncogenes). For more information about the BL-2 guidelines and adenovirus handling, refer to “Biosafety in Microbiological and Biomedical Laboratories,” 5th Edition. This may be downloaded at: www.cdc.gov/biosafety/publications/bmbl5/index.htm

The genomic copy of E1 in all 293 cell lines contains some homologous regions of overlap with our pAdeno vectors. In rare instances, it is possible for homologous recombination to occur between the E1 genomic region in 293 cells and the viral DNA, causing the gene of interest to be replaced with the E1 region, and resulting in generation of a “wild-type,” replication-competent adenovirus (RCA) (Lochmuller et al., 1994). This event is most likely to occur during large-scale preparations or amplification of virus, and the growth advantages of the RCA allow it to quickly overtake cultures of recombinant adenovirus. To reduce the possibility of generating RCA contaminated adenoviral stocks:

• Use caution when handling all viral preparations, and treat as BL-2 (see the previous page for more details).

• Screen for the presence of wild-type RCA contamination following large-scale viral preparations. Methods for RCA screening include PCR screening (Zhang et al., 1995) or supernatant rescue assays in non-E1 expressing cells (Dion et al., 1996).
Ligation and SwaI Digestion (to digest parental)

I-CeuI/PI-SceI Digestion (Pre-done by abm if Cat. No. A001)

Transformation and recombinant adenoviral DNA purification.

PacI Digestion (to linearize)

Transfect Low-passage HEK 293 cells

Collect recombinant adenovirus

**Figure 1**: Experimental flow chart of entire experiment, depending on your situation all or part of the chart may apply.
Figure 2: Maps of pShuttle(+) and pShuttle(-) and pAdeno.
Adeno-CMV Handbook

Adenoviruses enter target cells by binding to the Coxsackie/Adeno-virus Receptor (CAR) (Bergelson et al., 1997). After binding to the CAR, the adenovirus is internalized via integrin-mediated endocytosis (Russell, 2000) followed by active transport to the nucleus. Once in the nucleus, early genes, such as the E1 and E2, are expressed. This is followed by expression of the adenoviral late genes and viral genomic DNA replication. The presence of E1 protein is required for the expression of all late genes. For the generation of recombinant adenovirus using this kit, E1 is provided in trans by 293 packaging cells. For more information about the adenovirus life cycle and adenovirus biology, refer to published reviews (Russell, 2000).

Recombinant Protein Expression

After the adenovirus is translocated into the target cell’s nucleus, it does not integrate into the host genome. Therefore, expression of your recombinant protein of interest is detectable within 24 hours post infection and is transient in nature. The expression will persist as long as the viral genome is not degraded, which is about 1-2 weeks depending on the cell type. Longer expression can be observed in slow dividing cells such as neurons.

In vivo Gene Delivery

Recombinant adenoviruses have been shown to be the most efficient system for in vivo gene delivery applications. Many groups have successfully used adenoviral vectors to deliver target genes to a variety of tissues including the lungs, heart, brain and skeletal muscle. For detailed information about target genes that have been successfully expressed in vivo using recombinant adenovirus-based vectors, refer to published reviews (Russell, 2000; Wang and Huang, 2000; Wivel, 1999).
Table I. Adenovirus CMV Expression Kits

<table>
<thead>
<tr>
<th>Component</th>
<th>Cat. No.</th>
<th>Quantity</th>
<th>A100</th>
<th>A110</th>
<th>A120</th>
<th>A097</th>
<th>A098</th>
<th>A099</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linearized pAdeno DNA</td>
<td>A001</td>
<td>5ug</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>pShuttle(+) Vector</td>
<td>A002</td>
<td>5ug</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>pShuttle(-) Vector</td>
<td>A003</td>
<td>5ug</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>pShuttle-LacZ Control</td>
<td>A004</td>
<td>5ug</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Enzyme Pack w/ Buffers</td>
<td>A005</td>
<td>2 x 50ul</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>PCR Screening Sets</td>
<td>A006</td>
<td>2 x 100ul</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>293 Cells</td>
<td>A007</td>
<td>1x10⁶</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Ad-competent Cells</td>
<td>A014</td>
<td>10 x 50ul</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Glycogen 20mg/ml</td>
<td>A013</td>
<td>100ul</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

- Store Ad-Competent cells at -70°C and all other components at -20°C.
- Spin all items briefly before use to recover contents.
- Avoid repeated freeze-thaw cycles; make smaller aliquots if required.

Additional Materials Required

The following materials and reagents are required but not provided:

- Kanamycin (Cat. No. G022) and Ampicillin (Cat. No. G021)
- LB Broth/Liquid (Cat. No. G246) and LB Agar (Cat. No. G247)
- Glycogen, 20mg/ml (Cat. No. G024) and Cell Freezing Medium
- Agar (Cat. No. G060-1 or G060-2)
- Sterile, deionized H₂O, 100% Ethanol and 70% Ethanol.
- 10M (saturated solution) Ammonium Acetate (NH₄OAc) or 3M sodium acetate (NaOAc; pH 5.2)
- Electro- or Chemically Competent DH5α E. coli Cells (Cat. No. A014)
- Restriction Endonuclease Swal, Pacl, I-CeuI and PI-SceI (N.E.B.)
- T4 DNA Ligase (Invitrogen)
- Mini DNA Purification Kit (Cat. No. D024)
- Phenol:chloroform:isoamyl alcohol (25:24:1)
- 293 cell line (Cat. No. A007) and Trypsin-EDTA (Cat. No. TM050 or TM051)
- Dulbecco’s Modified Eagle’s Medium (Invitrogen Cat: 11995)
- Fetal bovine serum (FBS) (Cat. No. TM99-100 or TM999-500)
- Solution of 10,000 units/ml Penicillin G sodium and 10,000 μg/ml Streptomycin sulphate (Sigma Cat. No. P0781)
- Transfection reagent, and tissue culture plates and flasks
- Standard Phosphate-Buffered Saline (PBS) and Dulbecco’s Phosphate Buffered Saline (DPBS; VWR Cat. No. 82020-066)
Protocol

**NOTE:** The following protocol has been broken down into sections for convenience. However, time should be taken to familiarize oneself with the full procedure before attempting the experiment.

### A. Cloning Your Gene Into pShuttle

**Note:** Check for the following restriction sites in your gene of interest.

Although I-CeuI and PI-SceI sites are relatively rare, their presence will conflict with the subcloning of your gene of interest from the pShuttle vector into the pAdeno vector. Swal is used to eliminate background clones during the subcloning from pShuttle to pAdeno. PacI is used to linearize the recombinant adenoviral DNA before transfection into packaging 293 cells. Site-directed mutagenesis will need to be performed for gene inserts where any of these restriction sites exist.

**I-CeuI Recognition Sequence**

5′–TAACTATAACCGTCCTAAGGTAGCGA–3′
3′–ATTGATATTGCCAGGATTCCATCGCT–5′

**PI-SceI Recognition Sequence**

5′–ATCTATGTCGGGTGCGGAGAAAGGTAATGAAATGGCA–3′
3′–TAGATACAGCCACGCCT C T T T C T C C AT TACT T T ACCGT–5′

**PacI Recognition Sequence**

5′–TTAATTAA–3′
3′–AATTTAATT–5′

**Swal Recognition Sequence**

5′–ATTTAAAT–3′
3′–TAAATTA–5′

**Once it has been determined that there are no I-CeuI, PI-SceI, Swal, nor PacI sites in your gene of interest, subclone it into the pShuttle using any of the unique restriction sites located in the MCS region. Refer to Figure 2 (pg.4) for the availability of restriction sites. For more detailed information on molecular cloning, see Sambrook & Russell (2001) and Ausubel et al. (1995).**
B. Producing Recombinant Adenoviral DNA

1. PI-SceI/I-Ceul digestion of recombinant pShuttle:
   a. Prepare a 40μl PI-SceI/I-Ceul double-digest reaction of the pShuttle vector.
   b. Combine the reagents shown in Table II in a sterile 1.5ml microcentrifuge tube.

Table II. PI-SceI/I-Ceul Double Digest of pShuttle DNA

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>pShuttle or pShuttle-LacZ DNA</td>
<td>2-3ug</td>
</tr>
<tr>
<td>10X Double Digestion Buffer</td>
<td>4ul</td>
</tr>
<tr>
<td>PI-SceI Restriction Enzyme (1U/ul)</td>
<td>2ul</td>
</tr>
<tr>
<td>I-Ceul Restriction Enzyme (1U/ul)</td>
<td>2ul</td>
</tr>
<tr>
<td>10X BSA</td>
<td>4ul</td>
</tr>
<tr>
<td>ddH₂O</td>
<td>Variable</td>
</tr>
<tr>
<td>Total Reaction Volume</td>
<td>40ul</td>
</tr>
</tbody>
</table>

c. Mix well and spin briefly to collect liquid.

d. Incubate at 37°C for exactly 3 hours.

e. Perform a phenol:chloroform:isoamyl alcohol (25:24:1) extraction using the protocol in Appendix A (page 16).

2. Subclone the expression cassette of the pShuttle vector into the pAdeno genome:
   a. Combine the reagents shown in Table III in a sterile 1.5ml microcentrifuge tube in the order as shown.

Table III. Ligation of Recombinant Adenoviral DNA

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI-SceI/I-Ceul Digested Vector (Provided)</td>
<td>4ul</td>
</tr>
<tr>
<td>PI-SceI/I-Ceul Digested pShuttle</td>
<td>3ul</td>
</tr>
<tr>
<td>5X DNA Ligation Buffer</td>
<td>2ul</td>
</tr>
<tr>
<td>T4 DNA Ligase</td>
<td>1ul</td>
</tr>
<tr>
<td>Total Reaction Volume</td>
<td>10ul</td>
</tr>
</tbody>
</table>

b. Gently mix, then spin briefly in a microcentrifuge.

c. Incubate at room temperature for 1.5 hours.
Protocol

d. To the ligation product, add the reagents listed in Table IV.

Table IV. Linearization of Remaining Parental Vector

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ligation Product</td>
<td>10ul</td>
</tr>
<tr>
<td>10X SwaI Digestion Buffer</td>
<td>1.5ul</td>
</tr>
<tr>
<td>10X BSA</td>
<td>1.5ul</td>
</tr>
<tr>
<td>SwaI Enzyme</td>
<td>1ul</td>
</tr>
<tr>
<td>ddH₂O</td>
<td>1ul</td>
</tr>
<tr>
<td><strong>Total Reaction Volume</strong></td>
<td>15ul</td>
</tr>
</tbody>
</table>

e. Mix well and incubate at room temperature for an hour.


3. Transform E. coli with ligation products:

a. Transform electro- or chemically competent DH5α cells or Ad-competent (Cat No. A014) cells with the SwaI digestion (3-5μl).

b. Select for ampicillin-resistant (Ampr) transformants by plating the transformation mixture on a LB agar/Amp plate (100μg/ml ampicillin). Incubate overnight at 37°C.

c. Pick up 10 colonies and inoculate into 100μl LB/Amp medium in a sterile Eppendorf tube in the early morning.

d. After 5-6 hours of incubation, screen for positive clones by PCR with Adeno screening primer mix, see Appendix B (page 17).

e. When a bacterial clone carrying the desired recombinant has been identified, inoculate 100-500ml of LB/Amp medium with all the bacteria (100μl) from the 1.5 ml Eppendorf tube.

f. Incubate the culture at 37°C overnight.

g. Purify the plasmid using a Column Pure Plasmid Maxi-Prep Kit or an equivalent kit from Qiagen. Expected yield: 30-50μg plasmid DNA/100ml culture.

**Note:** pAdeno is a large plasmid (>30kb) that is susceptible to damage and rearrangement in E.coli. For best results, use fresh, log-phase cultures for purification of recombinant pAdeno DNA. Do not store culture at room temperature, 4°C, or on ice for long periods (i.e. >24 hours) before purification.

4. Analyze the Adenoviral DNA by PCR or restriction digestion.
C. PI-SceI and I-CeuI Restriction Analysis

The presence of the expression cassette can be verified by double digestion with PI-SceI and I-CeuI as shown in Table V. Analyze the digestion by electrophoresis on a 0.8–1.0% agarose/EtBr gel. The digestion will give rise to two fragments. The larger fragment is the pAdeno vector and the other is your gene insert cut out by PI-SceI and I-CeuI. Note: the insert fragment might appear much bigger than its actual predicted size due to the migration retardation by the binding of restriction enzymes of gene insert.

1. Set up the 30μl PI-SceI/I-CeuI double digests by combining the reagents in Table V in a sterile 1.5 ml microcentrifuge tube.

Table V. Restriction Analysis of Recombinant Adenoviral DNA

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenoviral DNA</td>
<td>2-3μg</td>
</tr>
<tr>
<td>10X Double Digestion Buffer</td>
<td>3μl</td>
</tr>
<tr>
<td>PI-SceI Restriction Enzyme (1U/μl)</td>
<td>2μl</td>
</tr>
<tr>
<td>I-CeuI Restriction Enzyme (1U/μl)</td>
<td>2μl</td>
</tr>
<tr>
<td>10X BSA</td>
<td>3μl</td>
</tr>
<tr>
<td>ddH&lt;sub&gt;2&lt;/sub&gt;O</td>
<td>Variable</td>
</tr>
<tr>
<td>Total Reaction Volume</td>
<td>15μl</td>
</tr>
</tbody>
</table>

2. Mix well and spin briefly to collect contents.

3. Incubate at 37°C for exactly 3 hours.

4. Verify the insert by electrophoresis on a 0.8-1.0% agarose/Safe-view™ (Cat. No. G108) gel. **Important:** Since I-CeuI and PI-SceI tend to remain bound to DNA after digestion, use a gel loading buffer that contains SDS (final concentration after combining with sample: 0.1%), heat to 65°C for 10 minutes before loading to dissociate the enzymes from the DNA.

D. PCR Analysis

Also, you can screen pAdeno DNA for the presence of pShuttle derived expression cassettes by PCR with Adeno forward and reverse PCR primers, see Appendix B (page 17). These primers specifically amplify a 350bp sequence that spans the multiple cloning site of pAdeno. Only recombinant Adenoviral templates are amplified since non-recombinants lack the pShuttle sequence needed for annealing with the forward primer.
Protocol

E. Preparing Adenoviral DNA for Transfection

1. In a sterile 1.5 ml microcentrifuge tube, combine the reagents in Table VI.

<table>
<thead>
<tr>
<th>Reagent</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recombinant Adenoviral DNA</td>
<td>5ug</td>
</tr>
<tr>
<td>10X Pacl Digestion Buffer</td>
<td>4ul</td>
</tr>
<tr>
<td>10X BSA</td>
<td>4ul</td>
</tr>
<tr>
<td>Pacl (10U/ul)</td>
<td>2ul</td>
</tr>
<tr>
<td>ddH2O</td>
<td>Variable</td>
</tr>
</tbody>
</table>

Total Reaction Volume 40ul

2. Mix contents well and spin the tube briefly.

3. Incubate at 37°C for 3 hours.

4. Perform phenol:chloroform extraction, Appendix A (page 16).

F. Generating Adenovirus in 293 Packaging Cells

1. Plate 293 cells at 70% confluency in a 6-well plate 12-24 hours before transfection.

2. Incubate the plate(s) at 37°C in a humidified atmosphere maintained at 5% CO2.

3. Transfect each 6 well culture plate with 5-7μl of PacI-digested recombinant Adenoviral DNA. Use DNAfectin™ (Cat. No. G061) to transfect DNA into 293 cells.

4. Subculture cells into a T75 flask using trypsin 3-5 days later.

5. Check periodically for cytopathic effect (CPE). Note: It normally takes 7-12 days to see CPE.

6. When >90% of the cells have detached from the plate, prepare viral stock by following steps 7-10. Name this stock “Primary Amplification” and store at -20°C.

   • Primary Amplification stock can be used for infecting target cells. We suggest evaluating the functionality of this viral stock before preparing a high-titre stock.

   • The presence of the recombinant construct can be verified by PCR or Western blotting.

7. Centrifuge the suspension at 1,500xg for 5 minutes at 23°C.
Protocol

8. Resuspend the pellet in 500μl sterile PBS.

9. Lyse cells with three consecutive freeze/thaw cycles. Freeze cells in dry ice/ethanol bath, thaw cells by placing the tube in a 37°C water bath. Do not allow suspension to reach 37°C.

10. After the third cycle, briefly centrifuge to pellet the cell debris. Transfer the lysate to a clean, sterile centrifuge tube and store the lysate at -20°C.


G. Amplification of Recombinant Adenoviral Vectors

The viral titre from the primary stock will be relatively low, further rounds of amplification are needed for 100% transduction in most target cells. In general, up to 2-3 rounds of amplification will give rise to titre of $10^6$ pfu/ml from 293 supernatant, which is enough for the transduction of most target cells in vitro at 70~100% efficiency. However, large-scale virus preparation is needed for most in vivo gene transfers. For detailed protocol of adenoviral amplification, please refer to Appendix C (page 18).

H. Determining Adenoviral Titre

There are three protocols for determining adenoviral titre:

1. Plaque Assay (requires ~2–3 weeks)

2. End-Point Dilution Assay (requires ~10 days)

3. OD$_{260}$ Assay (requires ~ 1 hour)

Methods 1 and 2 are biological assays; they measure the number of infectious viral particles. Method 3 on the other hand, is a physical assay; it measures the concentration of viral DNA and viral protein. Therefore, it does not distinguish between infectious and non-infectious viral particles.

For detailed information about adenoviral titre assay, please refer to our online technical support:

http://www.abmgood.com/Adenovirus-Plaque-Assay.html
Protocol

I. Transduction Procedure

If the virus is to be used in an *in vitro* transduction, double CsCl purification is not required as the viral supernatant will provide 100% gene transduction efficiency in most human cell lines. For *in vivo* studies (i.e. animal studies), purification is essential to remove defective particles, cell debris, and small amounts of media components, since these contaminants can induce significant immune responses. In addition, CsCl purification will concentrate the virus to a level suitable for *in vivo* injections.

1. **Prepare target cells in a 6-well plate or 10cm at 70% confluency** one day prior to transduction.

2. **Aspirate the culture medium and overlay with viral culture supernatant (1ml for a 6-well plate and 4-5ml for 10cm dishes)** to cover the cells for one hour in an incubator.

3. **Remove the media containing the virus and replace it with fresh complete media.**

4. **Gene transduction can be evaluated 48-72 hours after transduction** by different assays, such as microscope observation, if there is a colour-emitting reporter gene, Western blotting or qPCR analysis.
## Troubleshooting

<table>
<thead>
<tr>
<th>Problem</th>
<th>Possible Cause</th>
<th>Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>No Colonies After Transformation of pShuttle</td>
<td>Incorrect antibiotic used or antibiotic concentration too high.</td>
<td>Use Kanamycin at 50ug/ml of LB agar medium.</td>
</tr>
<tr>
<td></td>
<td>Poor transformation efficiency.</td>
<td>Check transformation efficiency using a control plasmid like pShuttle.</td>
</tr>
<tr>
<td>No Colonies After Transformation of pAdeno</td>
<td>Incorrect antibiotic used or antibiotic concentration too high.</td>
<td>Use Ampicillin at 100ug/ml of LB agar medium.</td>
</tr>
<tr>
<td></td>
<td>Poor transformation efficiency.</td>
<td>Check transformation efficiency using pAdeno.</td>
</tr>
<tr>
<td></td>
<td>Unsuccessful ligation.</td>
<td>Over digestion of pShuttle by PI-SceI or I-CeuI. Check digested products on agarose gel. Reduce the amount of enzyme or shorten the digestion period if a “smear” of bands is observed.</td>
</tr>
<tr>
<td>Too Many Background Colonies</td>
<td>Incomplete SwaI digestion.</td>
<td>Digest pAdeno with SwaI followed by transformation. Incubate longer or use more SwaI enzyme in the digestion.</td>
</tr>
<tr>
<td>Restriction Analysis of DNA Prepared from Large-Scale Culture</td>
<td>Mutation or recombination occurred.</td>
<td>pAdeno is a large plasmid and prone to recombination. Select a different clone or Maxi-DNA purification.</td>
</tr>
<tr>
<td>Reveals More Bands than Expected</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adeno DNA Resistant to Enzyme Digestion</td>
<td>Incompatible E. Coli strains were used for transformation.</td>
<td>Use an authentic DH5α strain for transformation.</td>
</tr>
<tr>
<td>No Virus Particles Produced</td>
<td>Poor transfection efficiency.</td>
<td>Check the transfection efficiency by a reporter gene, such as a GFP construct. A minimum 20-30% transfection is required. Adjust seeding density of cells to optimize confluency at time of infection.</td>
</tr>
<tr>
<td>293 cell culture used for transfection might be a late passage or too dense.</td>
<td></td>
<td>Start a fresh culture of 293 cells at low passage (p&lt;30). Transfect 293 cells at about 70% confluency.</td>
</tr>
<tr>
<td>Low quality pAdeno DNA.</td>
<td></td>
<td>Check the purity (A260/A280) and identity of the plasmid DNA used for transfection.</td>
</tr>
<tr>
<td>Too little or too much pAdeno DNA used.</td>
<td></td>
<td>Titrate the amount of PacI digested recombinant Adeno DNA to achieve maximal transfection efficiency. In general, 2-3ug of DNA is good for a 6-well size plate.</td>
</tr>
<tr>
<td>High Rate of Cell Death</td>
<td>Insert gene is toxic to 293 cells.</td>
<td>Make sure to use 293 cells from abm Inc. (Cat. No. A007). These cells have been optimized to be more tolerable to usually toxic genes.</td>
</tr>
</tbody>
</table>
References


Appendix A: Phenol:Chloroform:Isoamyl Alcohol Extraction

1. Top up the sample to 100μl with TE buffer (pH 8.0), then add 100μl phenol:chloroform:isoamyl alcohol (25:24:1).
2. Vortex thoroughly for 20 seconds.
3. Spin the tube in a microcentrifuge at 14,000rpm for 2 minutes at room temperature to separate the phases.
4. Carefully transfer the top aqueous layer to a clean 1.5ml tube.
5. Add 400μl 100% ethanol, 30μl 10M NH₄OAc (or 1/10 volume of 3 M NaOAc), and 1μl glycogen (20 mg/ml).
6. Vortex thoroughly for 20 seconds.
7. Spin the tube at 14,000rpm for 5 minutes at room temperature.
8. Remove and discard the supernatant.
9. Carefully overlay the pellet with 400μl 70% ethanol.
10. Spin the tube at 14,000rpm for 2 minutes at room temperature.
11. Carefully aspirate off the supernatant.
12. Air-dry the pellet for approximately 3-5 minutes at room temperature to evaporate the residual ethanol.
13. Dissolve the DNA in 10μl sterile 1X TE Buffer (pH 8.0) for downstream applications or store at -20°C until use.
Appendix B: Adenoviral DNA Screening by PCR

1. **Set up the reaction as follows using 2x PCR Taq MasterMix (Cat. No. G013) or your own Taq DNA polymerase. Make sure to include a negative control for each assay.**

   **Table VII. PCR Components**
<p>|</p>
<table>
<thead>
<tr>
<th>Reagent</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Template DNA (Bacterial or Purified)</td>
<td>1ul</td>
</tr>
<tr>
<td>Mixture of Forward &amp; Reverse Primers</td>
<td>2ul</td>
</tr>
<tr>
<td>ddH2O</td>
<td>22ul</td>
</tr>
<tr>
<td>2X PCR Taq Mastermix</td>
<td>25ul</td>
</tr>
<tr>
<td><strong>Total Reaction Volume</strong></td>
<td><strong>50ul</strong></td>
</tr>
</tbody>
</table>

2. **Perform PCR as follows:**

   **Table VIII. Thermocycler Conditions**

<table>
<thead>
<tr>
<th>Process</th>
<th>Temperature</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denaturation</td>
<td>95°C</td>
<td>4 minutes</td>
</tr>
<tr>
<td>PCR Cycles (30-35)</td>
<td>94°C</td>
<td>30 seconds</td>
</tr>
<tr>
<td></td>
<td>55°C</td>
<td>30 seconds</td>
</tr>
<tr>
<td></td>
<td>72°C</td>
<td>1 minute</td>
</tr>
<tr>
<td>Elongation</td>
<td>72°C</td>
<td>5 minutes</td>
</tr>
</tbody>
</table>

3. **After PCR, perform DNA agarose gel electrophoresis. These primers specifically amplify a 350-bp sequence that spans the cloning site in pAdeno. Only recombinant Adenoviral templates are amplified since non-recombinants lack the pShuttle sequence needed for annealing with the forward primer.**
Appendix C: Large-Scale Preparations of Virus

1. Depending on the required viral amount, one will need to grow up different quantities of 293 cells. For example, if 50ml viral supernatant is needed, five 10cm plates should be prepared. To achieve this, we recommend customers start growing 293 cells in one well of a 6-well plate and in one 10cm dish.

2. When cells are approximately 60-70% confluent in the 6-well plate, add 100μl of primary adenovirus stock to 0.5ml of complete culture medium. Aspirate the culture medium from the 6-well plate and then add the diluted virus onto the 293 cells slowly without dislodging the cells. Return the plate to the 37°C 5% CO₂ incubator for 1-2 hours before adding another 1.5ml of complete culture medium into the well. It will take 4-6 days to see over 95% of the cells are detached.

3. While adenoviral vectors are being replicated in the 6-well plate, subculture the 10cm dish to five 10cm dishes. When the 293 cells reach 70% confluence in the 10cm dishes, add 300-400μl of crude viral stock from the previous 6-well plate directly into the 10cm culture dishes.

4. It will take another 4-5 days before the completion of CPE. Collect all cells and culture medium into a 50ml culture tube. Freeze and thaw 3 times to release the viral particles from cells. Pellet the cell debris by centrifugation at 2,000g for 10 minutes.

5. Then the supernatant can be used for most in vitro transductions. Store the remaining virus at 4°C if you are going to use it for transduction or the next round of amplification (next step) within a couple of weeks. Store the virus at -70°C if you are not planning to use the virus for a while. Note: Adenoviral vectors are more stable at 4°C or at room temperature than lentiviral or retroviral vectors. After repeated testing, we found there is no significant loss of titre when stored at 4°C or room temperature for up to 72 hours. Virus will still be viable after one year of storage at 4°C, but long-term storage at -70°C in the presence of 5% glycerol is needed to minimize the stock titre loss.

6. For in vivo transduction using adenoviral vector, even greater virus production is needed. Up to fifty 15cm dishes of adenovirus can be amplified. The virus preparation can then be purified and concentrated by filter-based purification kit (A900) or CsCl banding.

7. Adenoviral vector titres are generally within the following ranges from different preparations. Note: Titres will be lower if gene is toxic to cells.

<table>
<thead>
<tr>
<th>Titre</th>
<th>Preparation</th>
</tr>
</thead>
<tbody>
<tr>
<td>10⁶</td>
<td>Original culture supernatant.</td>
</tr>
<tr>
<td>10⁷</td>
<td>Original culture (medium and cells) after freeze/thaw cycles (up to 3 cycles).</td>
</tr>
<tr>
<td>10⁸-10¹²</td>
<td>Purification by filter-based methods.</td>
</tr>
<tr>
<td>10⁹-10¹²</td>
<td>Purification by CsCl banding.</td>
</tr>
</tbody>
</table>
Contact Information

Applied Biological Materials Inc.

Website:  
www.abmGood.com

Phone:  
(8:30am-4:30pm PST M-F)  
Toll Free: 1-866-757-2414  
Local: (604) 247-2416  
Fax: (604) 247-2414 (24Hr.)

Address:  
Suite #8-13520 Crestwood Place  
Richmond, BC  
Canada V6V 2G2

Email:  
General Information: info@abmGood.com  
Order Products: order@abmGood.com  
Technical Support: technical@abmGood.com  
siRNA: siRNA@abmGood.com  
Business Development: bd@abmGood.com

Distributors

North America

Canada
Applied Biological Materials Inc.  
Tel: (604) 247-2416 / 1-866-757-2414  
Fax: (604) 247-2414  
www.abmGood.com

United States
Applied Biological Materials Inc.  
Tel: (604) 247-2416 / 1-866-757-2414  
Fax: (604) 247-2414  
www.abmGood.com

Mexico
Quimica Lavoisier S.A. de C.V.  
Tel: 52-333-848-8484  
Email: informes@lavoisier.com.mx  
www.lavoisier.com.mx

International

Australia
Biosensis Pty Ltd.  
Tel: +61 43 166 5519  
Email: sales@biosensis.com  
www.biosensis.com

Belgium
Gentaur  
Tel: 32 2 732 5688  
Email: ea@gentaur.com  
www.gentaur.com

France
Gentaur  
Tel: 01 43 25 01 50  
Email: ea@gentaur.com  
www.gentaur.com

Germany
BioCat GmbH  
Tel: +49 (0) 6221-714-1516  
Email: info@biocat.com  
www.biocat.com

India
G Biosciences  
Tel: 0120-432-3330  
Email: rohit@gbiosciences.com  
www.GBiosciences.com

Japan
Cosmo Bio Co. Ltd.  
Tel: 03-5632-9610/9620  
Email: mail@cosmobio.co.jp  
www.cosmobio.co.jp

Singapore
Bio-REV PTE  
Tel: (65) 6273-3022  
Email: allan@bio-rev.com  
bio-rev.com

South Korea
CMI Biotech  
Tel: 02 444 7101  
Email: cmibi@cmibi.com  
www.cmibi.com

Taiwan
Interlab Co. Ltd.  
Tel: +886-2-2736-7100  
Email: service@interlab.com.tw  
www.interlab.com.tw

United Kingdom
NBS Biologicals Ltd.  
Tel: +44 (0) 1480 433875  
Email: info@nbsbio.co.uk  
www.nbsbio.co.uk
The Source for any Antibody, siRNA, and Viral Vector

The Depot for PCR, qPCR, and Transfection Reagents